Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07811986 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

Name: HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease — clinical trial record (NCT07811986)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BEYOND-MM 001

StatusNot Yet Recruiting

PhasePhase 2

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Started2026-09-01

View on ClinicalTrials.gov ↗

Institute of Hematology & Blood Diseases Hospital, China

318 trials monitored

See 9 trials at risk

Multiple Myeloma

1,228 trials monitored

See 75 trials at risk

This is a prospective, single-arm, exploratory Phase II clinical study evaluating the efficacy and safety of HP-001 capsules in combination with dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) with extramedullary disease (EMD).

Trial Details

NCT Number	NCT07811986
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma (MM)
Enrollment	20 participants
Start Date	2026-09-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-10